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Abstract. A novel class of 5,6-dihydro-4H-benzo[d]isoxazol-7-ones and 5,6-dihydro-4H-
isoxazolo[5,4-c]pyridin-7-ones was designed, synthesized, and assayed to investigate their affinity 
to Hsp90 protein. 
The synthetic route was based on a 1,3-dipolar cycloaddition of nitriloxides, generated in situ from 
suitables benzaldoximes, to 2-bromocyclohex-2-enones or 3-bromo-5,6-dihydro-1H-pyridin-2-ones. 
Whereas all the compounds bearing a benzamide group on the bicyclic scaffold were devoid of 
activity, the derivatives carrying a resorcinol-like fragment showed a remarkable inhibitory effect 
on Hsp90. Docking calculations were performed to investigate the orientation of the new 
compounds within the binding site of the enzyme. 
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Heat shock protein 90 (Hsp90) is a molecular chaperone, which is essential for a wide range of 
protein assembly, trafficking, folding and degradation processes (1). Multiple signal transduction 
pathways implicated in the regulation of cell proliferation and survival are dependent on Hsp90 (2). 
Several Hsp90 client proteins are involved in critical processes, including cell-cycle regulation and 
apoptosis. The heat shock proteins are often overexpressed in tumour cells, and this supports their 
ability to survive under unfavourable stress conditions (e.g., hypoxia and acidosis), as well as to 
facilitate rapid somatic evolution (3).  
The discovery and characterization of natural compounds inhibiting Hsp90, such as geldanamycin 
and radicicol (Figure 1), have validated this molecular chaperone as a therapeutic target. 
Geldanamycin (4) inhibitory activity is mainly due to a competition with the ATP binding to the N-
terminus of the protein. Radicicol (5), a natural macrocyclic antifungal antibiotic, inhibits Hsp90 by 
interacting with the same site of action of geldanamycin. Due to its chemical instability, this 
compound could not be developed, but it served as a template for the discovery of new Hsp90 
inhibitors. In particular, the presence of a resorcinol-like fragment was found to be extremely 
important to drive the binding mode and to get a strong interaction with the enzyme either in 
radicicol and other synthetic series of compounds (6-8). 
The investigation and clinical development of Hsp90 inhibitors continue to progress. Currently, a 
number of highly specific compounds are undergoing clinical trials, and an impressive growth in 
scientific literature confirms the great interest towards this target (9). However, to date, there are no 
FDA approved Hsp90-targeting agents for clinical use. For all these reasons, the finding of novel 
chemotypes that fully satisfy requisites of safety and stability still remains an interesting and 
promising goal. 
 
Previous reports supported the hypothesis that the presence of the isoxazole nucleus could exert a 
key role in the docking of compounds to the ATP binding site of the enzyme. In fact, synthetic 
compounds containing this heterocyclic moiety have shown potent and selective inhibition of 
Hsp90 (6,10,11). 
Recently, a structural investigation on the isoxazole scaffold led us to discover a new class of 
4,5,6,7-tetrahydroisoxazolo-[4,5-c]pyridines containing an isoxazole nucleus fused with a 
tetrahydropyridine ring (12). Other structures described in recent papers, containing condensed 
bicyclic groups, have been very successful in targeting Hsp 90 (7,8,13). Thus, we envisaged that the 
isoxazole scaffold could be fused to other rings in order to build novel series of potential Hsp90 
inhibitors with a bicyclic core structure. 
Based on preliminary computational fitting experiments of isoxazole-based molecules on the Hsp90 
X-ray structure, we selected compounds with a 5,6-dihydro-4H-benzo[d]isoxazol-7-one (1, X = 
CH2, Scheme 1) or a 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one (1, X = NH, Scheme 1) scaffold 
as starting points for further investigation. Our exploration was focused on the expansion of the core 
structure within the ATP binding site, by adding groups able to improve its fitting to the pocket. In 
particular, we planned to link the bicyclic system either to a resorcinol-like group or to a primary 
benzamide moiety, being both these fragments able to confer tight binding into the ATP binding 
pocket (14).  
 
O
O
O
N
H
OMe
O
OMe
O NH2
OMe
Geldanamycin (GDA)
O
O
O
N
H
OMe
O
OMe
O NH2
H
N
17-AAG
HO
OO
O
O
OHHO
Cl
Radicicol
HO
OH
N
O
CONHEt
NPV-AUY922
N
O
N
N
NH
CONH2
O
O
NH2
CF3O
SNX5422
N
N NH
N
OH
HO
O
STA9090
HO
OH
N
O NHCO
NHCOEt
SST0116CL1
N
O
 
 
Figure 1. Hsp90 inhibitors. 
 
The synthetic route used for the preparation of compounds 1 was based on a 1,3-dipolar 
cycloaddition of nitriloxides, generated in situ from suitables benzaldoximes, to 2-bromocyclohex-
2-enones or 3-bromo-5,6-dihydro-1H-pyridin-2-ones. (Scheme 1) 
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Scheme 1  
 
Literature reports (15) show that cycloaddition of arylnitriloxides to cyclohexenones affords 4-
acylisoxazolines. Similarly, cycloaddition to α, β-unsaturated lactams affords mainly 4-
carboxamidoisoxazolines with high regioselectivity (16). Thus, in order to reverse the 
regiochemistry of the reaction, we planned to use lactams and ketones with a bromine atom in alfa 
position with respect to the carbonyl group. Following this strategy, the isoxazole could be obtained 
in one step, due to the spontaneous isoxazoline dehydrobromination. 
The key fragment 5 was obtained in three steps, starting from commercially available 2,4-
dihydroxybenzaldehyde 4 (Scheme 2). Chlorination of 4 with NCS, followed by protection of the 
phenol groups with 2-methoxyethoxymethyl chloride, afforded 5-chloro-2,4-bis-(2-
methoxyethoxymethoxy)benzaldehyde. This intermediate was then converted into the 
corresponding oxime 5 by reaction with NH2OH∙HCl and pyridine in ethanol. 
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Scheme 2 
 
Compound 7a was obtained starting from N-methylpiperidone, which was brominated to obtain 1-
methy-3,3-dibromo-2-piperidone (17). Dehydrobromination with CaCO3 in DMF at 80°C gave 7a 
in good yield (18). Similarly, compound 7b was obtained from δ-valerolactone (19). Cycloaddition 
of 5 to 7a and 7b was performed in dichloromethane at room temperature by generating the 
nitriloxide in situ with NCS and Al2O3, to obtain 8a and 8b, respectively (20). Finally, deprotection 
of the phenol groups gave compounds 9a-b. 
Cycloaddition of 5 to 11, on its turn obtained from cyclohexen-2-one (21), afforded 12, which was 
deprotected by 10% HCl to give 13 (Scheme 3). To investigate the role of the carbonyl group in 13, 
a series of analogues were prepared starting from the intermediate 12. Treatment with NaBH4 and 
CeCl3, followed by HCl, gave the reduced compound 14. Reaction of 12 with hydroxylamine 
hydrochloride and O-(2-aminoethylhydroxylamine) gave the oximes 15 and 16, respectively.  
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Scheme 3 
 
A series of analogues with the benzamide moiety was prepared following the same synthetic 
strategy (Scheme 4). The 4-(hydroxyiminomethyl)benzonitrile 18 was prepared from 4-
cyanobenzaldehyde 17 by reaction with hydroxylamine hydrochloride and pyridine in ethanol (22). 
The cycloaddition reaction, performed following the conditions previously described, afforded 19 in 
20% yield. The yield was increased to 38% when the 4-cyanobenzaldehye chlorooxime obtained 
reacting 19 with N-chlorosuccinimide in DMF, was reacted with the dipolarophile 11 in the 
presence of (Bu3Sn)2O at room temperature (23). Amide 20 was obtained by reaction of 19 with 
H2O2 and NaOH. Similarly to compound 13, compound 20 was converted to oximes 21a-c by 
reaction with suitable hydroxylamines, whereas compound 22 was obtained by reduction with 
NaBH4, followed by treatment with H2O2.  
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Scheme 4 
 
The binding affinity to Hsp90 of synthesized compounds was determined by a fluorescence 
polarization (FP) assay (24). The results are summarized in Table 1. 
 
Table 1. Binding affinity to Hsp90 of synthesized compounds. 
Compound Hsp90 (FP) (IC50, µM) 
17-AAG 1.09±0.05 
9a 10.0±0.8 
9b 1.60±0.04 
13 4.8±0.1 
14 26±1 
15 0.8±0.1 
16 6.3±0.1 
20 >100 
21a >100 
21b >100 
21c >100 
22 >100 
The most striking result was the lack of activity showed by compounds carrying the benzamide 
moiety. In fact, either the parent compound 20 or the derivatives 21a-c and 22 were devoid of 
Hsp90 inhibitory activity. The compounds with a resorcinol-like moiety appeared more promising. 
In fact, almost all the tested compounds showed inhibitory activity with IC50 less than 10 µM. 
Compound 15, with an oxime group, showed a notable binding ability (IC50 = 0.8 µM). The 
reduction of the carbonyl group (as in 14) caused a decrease of activity. (IC50 = 26 µM). Also the 
introduction of a methyl group on the dihydropyridone moiety (9b vs 9a) resulted detrimental for 
activity. 
According to the previous data, the compounds with the resorcinol fragment (9a-b, 13-16) showed 
the most interesting profile, and two of them (namely, 9b and 15) had ability to bind Hsp90 
comparable to or slightly better than that of the reference compound 17-AAG (1.6 and 0.8 µM vs 
1.1 µM, respectively). 
To gain a more precise picture of the interaction mode of these compounds with Hsp90, a 
computational protocol consisting in molecular docking calculations and energy minimization of 
the resulting complexes was set up. For this purpose, the structure of Hsp90 was taken from the 
crystallographic coordinates of its complex with NVP-AUY933 (PDB entry 2VCI) (6) and used as a 
template. Docking simulations and energy minimization were performed as previously described for 
other Hsp90 triazole inhibitors (25). 
An analysis of the complexes resulting from docking calculations showed that the orientation of the 
new compounds 9a-b, 13-16 within the binding site is very similar to that previously found for 
different Hsp90 inhibitors (25), with the resorcinol moiety deeply located within the cavity, while 
the remaining part of the molecule pointed toward the solvent (Figure 2). In further detail, the o-
hydroxy group is involved in a direct and in a water-bridged (HOH2233) hydrogen bond with the 
terminal carboxyl group of Asp93. On the other hand, the p-hydroxy group makes a water-mediated 
(HOH2232) hydrogen bond with the carbonyl group of Leu48. The chlorine atom is accommodated 
by a large hydrophobic cavity delimited by Phe138 and Leu107 side chains. Moreover, also the 
isoxazole nitrogen atom interacts with the carboxyl terminus of Asp93 by a water-mediated 
(HOH2233) hydrogen bond. The oxime nitrogen of the most active compound (15) interacts with 
the ammonium group of the Lys58 side chain, whereas the endocyclic oxygen is involved in a 
intramolecular hydrogen bond with the terminal OH group of the oxime moiety. The saturated 
portion of the six-membered condensed ring does not show any significant hydrophobic interaction 
with the protein. 
 
 Figure 2. Graphical representation of the complex between Hsp90 and 15 (ball and stick notation) 
as derived from molecular docking calculations and energy minimization. The resorcinol hydroxy 
groups and the isoxazole nitrogen atom make hydrogen bond interactions mediated by water 
molecules (W). The carboxy terminus of Asp93 interacts directly with the o-hydroxy group of the 
ligand. The oxime OH group makes an intramolecular hydrogen bond with the heterocyclic oxygen, 
while the oxime nitrogen atom interacts by hydrogen bond with the terminal ammonium group of 
Lys58 side chain. Hydrophobic contacts between the chlorine substituent and the side chains of 
Phe138 and Leu107 are also found. For the sake of clarity, only few amino acid residues are 
displayed and labeled, while hydrogen bonds are depicted as dashed black lines. 
 
In summary, we have designed and synthesized a novel class of 5,6-dihydro-4H-benzo[d]isoxazol-
7-ones and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-ones to investigate their affinity to Hsp90 
protein. Whereas all the compounds having a benzamide group on the bicyclic scaffold were devoid 
of activity, all the derivatives carrying a resorcinol-like fragment showed an inhibitory effect on the 
enzyme. In particular, 15 possessed a remarkable binding ability (IC50 = 0.8 µM), slightly better 
than that of the reference compound (17-AAG). On this basis, it could be considered as a useful 
starting point for medicinal chemists involved in designing new scaffolds in the field of Hsp90 
inhibitors. 
Work is in progress to investigate structural changes of the resorcinol portion, as well as of the 
bicyclic moiety, to enhance the fitting into the Hsp90 ATP binding pocket and to improve the 
activity of the compounds. 
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